|
1
|
Govindan R, Page N, Morgensztern D, Read
W, Tierney R, Vlahiotis A, Spitznagel EL and Piccirillo J: Changing
epidemiology of small-cell lung cancer in the United States over
the last 30 years: Analysis of the surveillance, epidemiologic and
end results database. J Clin Oncol. 24:4539–4544. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sabari JK, Lok BH, Laird JH, Poirier JT
and Rudin CM: Unravelling the biology of SCLC: Implications for
therapy. Nat Rev Clin Oncol. 14:549–561. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Koinis F, Kotsakis A and Georgoulias V:
Small cell lung cancer (SCLC): No treatment advances in recent
years. Transl Lung Cancer Res. 5:39–50. 2016.PubMed/NCBI
|
|
4
|
Saito M, Suzuki H, Kono K, Takenoshita S
and Kohno T: Treatment of lung adenocarcinoma by molecular-targeted
therapy and immunotherapy. Surg Today. 2017.
|
|
5
|
George J, Lim JS, Jang SJ, Cun Y, Ozretić
L, Kong G, Leenders F, Lu X, Fernández-Cuesta L, Bosco G, et al:
Comprehensive genomic profiles of small cell lung cancer. Nature.
524:47–53. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iwakawa R, Kohno T, Totoki Y, Shibata T,
Tsuchihara K, Mimaki S, Tsuta K, Narita Y, Nishikawa R, Noguchi M,
et al: Expression and clinical significance of genes frequently
mutated in small cell lung cancers defined by whole exome/RNA
sequencing. Carcinogenesis. 36:616–621. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Iwakawa R, Takenaka M, Kohno T, Shimada Y,
Totoki Y, Shibata T, Tsuta K, Nishikawa R, Noguchi M, Sato-Otsubo
A, et al: Genome-wide identification of genes with amplification
and/or fusion in small cell lung cancer. Genes Chromosomes Cancer.
52:802–816. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Semenova EA, Nagel R and Berns A: Origins,
genetic landscape and emerging therapies of small cell lung cancer.
Genes Dev. 29:1447–1462. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity and immune correlates
of anti-PD-1 antibody in cancer. N Engl J Med. 366:2443–2454. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gettinger S, Rizvi NA, Chow LQ, Borghaei
H, Brahmer J, Ready N, Gerber DE, Shepherd FA, Antonia S, Goldman
JW, et al: Nivolumab monotherapy for first-line treatment of
advanced non-small-cell lung cancer. J Clin Oncol. 34:2980–2987.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rizvi NA, Hellmann MD, Brahmer JR,
Juergens RA, Borghaei H, Gettinger S, Chow LQ, Gerber DE, Laurie
SA, Goldman JW, et al: Nivolumab in combination with platinum-based
doublet chemotherapy for first-line treatment of advanced
non-small-cell lung cancer. J Clin Oncol. 34:2969–2979. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Herbst RS, Soria JC, Kowanetz M, Fine GD,
Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger
SN, et al: Predictive correlates of response to the anti-PD-L1
antibody MPDL3280A in cancer patients. Nature. 515:563–567. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Garon EB, Rizvi NA, Hui R, Leighl N,
Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L,
et al: KEYNOTE-001 Investigators: Pembrolizumab for the treatment
of non-small-cell lung cancer. N Engl J Med. 372:2018–2028. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Taube JM, Klein A, Brahmer JR, Xu H, Pan
X, Kim JH, Chen L, Pardoll DM, Topalian SL and Anders RA:
Association of PD-1, PD-1 ligands and other features of the tumor
immune microenvironment with response to anti-PD-1 therapy. Clin
Cancer Res. 20:5064–5074. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: KEYNOTE-024 Investigators: Pembrolizumab versus
chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl
J Med. 375:1823–1833. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
George J, Saito M, Tsuta K, Iwakawa R,
Shiraishi K, Scheel AH, Uchida S, Watanabe SI, Nishikawa R, Noguchi
M, et al: Genomic amplification of CD274 (PD-L1) in small-cell lung
cancer. Clin Cancer Res. 23:1220–1226. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Saunders LR, Bankovich AJ, Anderson WC,
Aujay MA, Bheddah S, Black K, Desai R, Escarpe PA, Hampl J, Laysang
A, et al: A DLL3-targeted antibody-drug conjugate eradicates
high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.
Sci Transl Med. 7:302ra1362015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rudin CM, Pietanza MC, Bauer TM, Ready N,
Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA III,
Robert F, et al: Rovalpituzumab tesirine, a DLL3-targeted
antibody-drug conjugate, in recurrent small-cell lung cancer: A
first-in-human, first-in-class, open-label, phase 1 study. Lancet
Oncol. 18:42–51. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gardner EE, Lok BH, Schneeberger VE,
Desmeules P, Miles LA, Arnold PK, Ni A, Khodos I, de Stanchina E,
Nguyen T, et al: Chemosensitive relapse in small cell lung cancer
proceeds through an EZH2-SLFN11 axis. Cancer Cell. 31:286–299.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sobin LH and Compton CC: TNM seventh
edition: What's new, what's changed: Communication from the
international union against cancer and the American joint committee
on cancer. Cancer. 116:5336–5339. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sobin LH, Gospodarowicz M, Wittekind C and
Wittekind Ch: International Union Against Cancer (UICC) TNM
Classification of Malignant Tumors. 7th. Wiley-Blackwell; Oxford
UK: 2009
|
|
24
|
Lu C, Han HD, Mangala LS, Ali-Fehmi R,
Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, et
al: Regulation of tumor angiogenesis by EZH2. Cancer Cell.
18:185–197. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guan J, Lim KS, Mekhail T and Chang CC:
Programmed death ligand-1 (PD-L1) expression in the programmed
death receptor-1 (PD-1)/PD-L1 blockade: A key player against
various cancers. Arch Pathol Lab Med. 141:851–861. 2017. View Article : Google Scholar : PubMed/NCBI
|
